Severe exacerbations requiring hospitalisation over the study period · adults with asthma
ICS dose reduction showed no clear difference in exacerbation requiring hospitalisation compared with no change (low certainty).
1 finding from 1 review
FEV1 · adults with asthma
1 finding from 1 review
Asthma control · adults with asthma
1 finding from 1 review
Steroid‐related AEs · adults with asthma
It is very uncertain whether ICS dose reduction changes steroid‐related AEs compared with no change (very low certainty).
1 finding from 1 review
Change in AQLQ · adults with asthma
1 finding from 1 review
FEV1 (L) · adults with asthma
1 finding from 1 review
Exacerbation: hospital 17 weeks · adults with asthma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Asthma control (short asthma morbidity score) · adults with asthma
1 finding from 1 review
Nausea · participants with advanced cancer who have nausea and vomiting not related to chemotherapy, radiotherapy, or surgery
1 finding from 1 review
Number of vomiting episodes · participants with advanced cancer who have nausea and vomiting not related to chemotherapy, radiotherapy, or surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · participants with advanced cancer who have nausea and vomiting not related to chemotherapy, radiotherapy, or surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · participants with advanced cancer who have nausea and vomiting not related to chemotherapy, radiotherapy, or surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient satisfaction · participants with advanced cancer who have nausea and vomiting not related to chemotherapy, radiotherapy, or surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Improvement in disability grade after 4 weeks · patients with Guillain‐Barré syndrome
4 findings from 1 review
no estimate extracted
6 studies · 587 participants
Moderate
no estimate extracted
4 studies · 120 participants
Very low
no estimate extracted
2 studies · 467 participants
Moderate
Show 1 more finding
Death or disability after 1 year · patients with Guillain‐Barré syndrome
Corticosteroid showed no clear difference in death or disability after 1 year compared with control (moderate certainty).
1 finding from 1 review
Adverse events ‐ Diabetes mellitus requiring insulin · patients with Guillain‐Barré syndrome
Corticosteroid leads to higher adverse events ‐ diabetes mellitus requiring insulin compared with control (high certainty).
1 finding from 1 review
Adverse events: hypertension · patients with Guillain‐Barré syndrome
Corticosteroid leads to lower adverse events ‐ hypertension compared with control (high certainty).
1 finding from 1 review
Death · adults or children with tuberculous meningitis on tuberculosis (TB) chemotherapy
Any corticosteroid leads to lower death compared with control (high certainty).
1 finding from 1 review
Disabling neurological deficit · adults or children with tuberculous meningitis on tuberculosis (TB) chemotherapy
Any corticosteroid showed no clear difference in disabling neurological deficit compared with control (low certainty).
1 finding from 1 review
Change in muscle strength ‐ QMT leg score (lb) · patients with Duchenne muscular dystrophy
1 finding from 1 review